Understanding Standard of Care in Immunology
Background | Client keen to understand effectiveness, tolerability and safety of a protein tyrosine kinase inhibitor (TKI) in patients with CML used during routine clinical practice. Data collected to date was limited, but clinicians were keen to see further evidence in all aspects. |
RWD Solution | An international, multi-centre, retrospective, non-interventional research study. Approval was gained from HRA, ethics, NIHR portfolio and local research and development departments. Following consent, data was collected from patient medical records, cleaned centrally and analysed by pH. |
Outputs |
|
Related posts